Flixotide Disk, 50 μg/inhalation dose, inhalation powder
Flixotide Disk, 100 μg/inhalation dose, inhalation powder
Flixotide Disk, 250 μg/inhalation dose, inhalation powder
Flixotide Disk, 500 μg/inhalation dose, inhalation powder
Fluticasone propionate
Flixotide Disk belongs to a group of medicines used in obstructive airway diseases.
The active substance of the medicine, fluticasone propionate, is a corticosteroid with local anti-inflammatory action in the lungs.
Flixotide Disk is indicated for:
In adults:
mild asthma - in patients who require daily symptomatic treatment with bronchodilators;
moderate asthma - unstable or worsening asthma, despite regular use of preventive medications or only bronchodilators;
severe asthma - in patients with severe chronic asthma and requiring oral steroids to control symptoms. Starting inhaled fluticasone propionate in many people allows for a reduction or complete discontinuation of oral steroids.
In childrenwho require preventive medication, including patients who have not responded to other available preventive medications.
Fluticasone propionate is indicated for the treatment of COPD, in combination with a long-acting beta-agonist, such as salmeterol.
Only Flixotide Disk, inhalation powder with a strength of 250 μg/inhalation dose and 500 μg/inhalation dose, are suitable for this indication.
If asthma symptoms worsen or asthma control deteriorates, i.e.if wheezing worsens or it is necessary to use a larger number of inhalations of a rapid-acting inhalation medicine to facilitate breathing, the patient should continue using the medicine and contact their doctor immediately, who will assess the patient's condition and recommend appropriate treatment.
Flixotide Disk should not be used to interrupt a sudden asthma attack. For this purpose, a rapid-acting bronchodilator (e.g., salbutamol) should be used, which the patient should always carry with them. Care should be taken not to confuse Flixotide Disk with an inhalation medicine used as needed.
Prolonged use of Flixotide Disk may lead to suppression of the natural production of steroid hormones by the adrenal glands. This may cause a decrease in bone mass, cataracts, glaucoma, weight gain, rounding of the face (moon face), high blood pressure, slowed growth in children and adolescents.
The doctor will regularly check if the patient is not experiencing any of these side effects and ensure that the patient is using the smallest dose of Flixotide Disk that provides adequate control of asthma and COPD.
During the use of fluticasone propionate in recommended doses, adrenal cortex function usually remains normal. Nevertheless, in people previously treated with oral steroids, symptoms of impaired adrenal cortex function may occur. Long-term treatment with high doses of inhaled steroids may cause suppression of adrenal cortex function. Children and adolescents under 16 years of age, taking large (usually ≥1000 micrograms per day) doses of fluticasone propionate, are at particular risk. Very rare side effects may occur when taking large doses of Flixotide Disk for a long time or when suddenly stopping treatment or reducing the dose. Side effects may also occur in the event of infections or during periods of severe stress (e.g., accident or surgery). The symptoms are not usually characteristic and may include: abdominal pain, fatigue, loss of appetite, nausea and vomiting, weight loss, headache, confusion, low blood pressure, decreased blood glucose levels, and seizures. To prevent these symptoms, the doctor may prescribe additional corticosteroids to be taken at that time.
Due to the possibility of impaired adrenal cortex function, patients who are being switched from oral steroid medications to inhaled fluticasone propionate should be under special care, and adrenal cortex function should be monitored.
After introducing fluticasone propionate into treatment, the reduction of oral steroid doses should be gradual, and patients should carry a "steroid card" informing about the need to administer additional oral steroids in case of stress.
Replacing oral steroids with inhaled medications may reveal allergic symptoms, such as: allergic rhinitis or rash, which were previously treated with oral steroids. The doctor will recommend appropriate treatment.
There have been reports of an increased number of cases of pneumonia in clinical trials in patients with chronic obstructive pulmonary disease (COPD) receiving fluticasone propionate at a dose of 500 micrograms (see section 4). The doctor should monitor patients with COPD to detect whether they are developing pneumonia, as the clinical symptoms of pneumonia and COPD exacerbation may often overlap.
Very rare cases of increased blood glucose levels have been reported (see section 4), and the doctor should take this into account when prescribing Flixotide Disk to patients with a history of diabetes.
Do not stop treatment with fluticasone propionate suddenly.
If the patient is currently being treated or has been treated for tuberculosis, they should inform their doctor.
If the patient experiences blurred vision or other vision disturbances that may be caused by cataracts or glaucoma, they should contact their doctor.
Tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take, including those available without a prescription.
It is especially important to tell your doctor about any of the following medicines that you are currently taking or have recently taken:
The doctor will assess whether Flixotide Disk can be used with these medicines. Some of them may enhance the effect of Flixotide Disk, and the doctor may want to closely monitor the patient's condition when taking such medicines (including some HIV medicines: ritonavir, cobicistat).
Only medicines recommended by the doctor should be used with Flixotide Disk.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before using this medicine.
The doctor will assess whether you can use Flixotide Disk during this period.
It is unlikely that side effects associated with the use of Flixotide Disk will affect your ability to drive or use machines.
Each dose of Flixotide Disk contains approximately 12.5 mg of lactose. In people with lactose intolerance, this amount of lactose usually does not cause any problems. If you have previously been diagnosed with intolerance to some sugars, you should consult your doctor before taking the medicine.
This medicine should always be used as directed by your doctor. Do not take a higher dose than recommended. If in doubt, consult your doctor.
Flixotide Disk is for inhalation use only.
The doctor will adjust the dose of the medicine according to the individual patient's response to treatment and determine the smallest dose that provides effective control of symptoms.
It is very important to use Flixotide Disk every day, until the doctor recommends otherwise. The therapeutic effect occurs within 4 to 7 days.
From 100 μg to 1000 μg twice a day. The initial dose of the medicine depends on the severity of the disease.
Children over 4 years old
From 50 μg to 100 μg twice a day. The initial dose of the medicine depends on the severity of the disease.
Children under 4 years old
Flixotide Disk is not intended for use in children under 4 years old.
500 μg twice a day, which corresponds to 1 dose of Flixotide Disk, 500 μg/inhalation dose, twice a day, or 2 doses of Flixotide Disk, 250 μg/inhalation dose, twice a day, in combination with a long-acting beta-agonist, such as salmeterol.
Only Flixotide Disk, inhalation powder with a strength of 250 μg/inhalation dose and 500 μg/inhalation dose, are suitable for this dose.
The medicine must be used daily to achieve optimal benefit, which may take 3 to 6 months.
If there is no improvement, the patient should be re-evaluated clinically.
Special patient groups
There is no need to change the dosage in elderly patients or patients with renal or hepatic impairment.
Using the Disk inhaler
After sliding the slider of the Disk inhaler, a small hole appears in the mouthpiece, and the dose of the medicine is ready for inhalation. After closing the Disk inhaler, the slider automatically returns to its original position, and the outer cover protects the Disk when not in use. To use, follow the steps below:
Rinsing the mouth with water and spitting it out after inhaling the medicine helps prevent hoarseness and thrush.
Cleaning
To clean the mouthpiece of the Disk inhaler, wipe it with a dry, soft cloth.
In the event of using a higher dose of Flixotide Disk than recommended, consult your doctor or pharmacist immediately for advice.
It is important to use the doses of the medicine as recommended by the doctor. Do not increase or decrease the dose without consulting your doctor.
Using higher doses of fluticasone propionate than recommended may cause temporary suppression of adrenal cortex function.
Long-term use of higher doses of fluticasone propionate than recommended may lead to adrenal insufficiency.
It is very important to take the recommended dose of the medicine every day to ensure the greatest effectiveness of the treatment.
If a dose is missed, take the medicine as soon as possible. Continue treatment as before.
Do not take a double dose to make up for a missed dose.
It is very important to take Flixotide Disk every day, until the doctor recommends stopping treatment. Do not stop taking Flixotide Disk suddenly, as the symptoms of the disease may worsen and hormonal disorders may occur in the body.
If you have any further doubts about the use of this medicine, consult your doctor or pharmacist.
Like all medicines, Flixotide Disk can cause side effects, although not everybody gets them.
The following side effects have been observed in patients taking Flixotide Disk.
Allergic reactionsto Flixotide Disk, which occur uncommonly ( may occur in 1 to 10 out of 1000 patients taking the medicine). They are characterized by symptoms such as:
Allergic reactionsto Flixotide Disk, which occur very rarely ( may occur in less than 1 out of 10,000 patients taking the medicine), and in a small number of patients, these reactions may develop into a serious condition, even life-threatening, if not treated. They are characterized by symptoms such as:
Tell your doctorif any of the following symptoms occur while using Flixotide Disk - they may be symptoms of a lung infection:
Other side effects:
Very common side effects( may occur in more than 1 in 10 patients):
Common side effects( may occur in 1 to 10 out of 100 patients):
Rare side effects( may occur in 1 to 10 out of 10,000 patients):
Very rare side effects( may occur in less than 1 in 10,000 patients):
Side effects with unknown frequency( frequency cannot be estimated from the available data):
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of the medicine.
Side effects can also be reported to the marketing authorization holder or its representative.
Store at a temperature not exceeding 30°C.
Store out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after EXP.
The expiry date refers to the last day of the month.
The batch number of the medicine is stated on the packaging after: Lot.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Flixotide Disk is a powder for inhalation.
The packaging contains 60 doses of the medicine in the form of powder, placed in a multi-layered foil in a plastic container (Disk inhaler), equipped with a mouthpiece and dose counter, packaged in foil, in a cardboard box.
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
D24 YK11
Ireland
For more detailed information, please contact the representative of the marketing authorization holder:
GSK Services Sp. z o.o.
ul. Rzymowskiego 53
02-697 Warsaw
phone: (22) 576-90-00
{ Logo of the marketing authorization holder}
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.